Advocacy intelligence hub — real-time data for patient organizations
Ryplazim: FDA approved
Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Ryplazim
ProMetic BioTherapeutics, Inc.
Ryplazim
(plasminogen, human-tvmh)Orphan drugProMetic BioTherapeutics, Inc.
Epogen
(Epoetin alfa)Orphan drugstandardAmgen, Inc.
12.1 Mechanism of Action Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
Jean-Baptiste Arnoux
Hopital Necker-Enfants Malades
Anders Bröijersén, MD
Swedish Orphan Biovitrum
Gary Hubbard, Dr
Nutricia UK Ltd
📍 Birmingham
Anita MacDonald
Birmingham Women's and Children's NHS Foundation Trust
📍 Birmingham
André Nell
+27 51 410 3046
Erik Brouwer, MD
Swedish Orphan Biovitrum